Gerardo Musuraca

Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibi- tor, was approved by the US FDA for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) o...

Gerardo Musuraca ;

Michele Merli ;

Roberto Marasca ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Pier Luigi Zinzani ;

Eric Jacobsen ;

Juraj Ura ;

Kirit Ardeshna ;

Mohamad Cherry ;

Fritz Offner ;

Jiri Mayer ;

Fontanet Bijou ;

Monica Tani ;

10/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Gerardo Musuraca

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products